Identifying biomarkers for diagnosing sepsis in the emergency room
Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room
This study is trying to find out if certain immune responses can help doctors spot sepsis in patients with infections when they arrive at the emergency room.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Academic / other |
| Locations | 3 sites (Almere Stad, Flevoland and 2 other locations) |
| Trial ID | NCT06178822 on ClinicalTrials.gov |
What this trial studies
This observational study aims to compare the immune responses of patients with and without sepsis who present to the emergency department with suspected infections. It seeks to identify immune response abnormalities that may indicate an increased risk of developing sepsis in patients initially presenting without it. Additionally, the study will assess the long-term cognitive and physical effects of sepsis on patients after their admission. The research will utilize the SOFA score to define sepsis and will adapt the assessment of respiratory function for emergency settings.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 years or older who present to the emergency department with a clinical suspicion of infection.
Not a fit: Patients who do not provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic methods for sepsis, enabling timely and effective treatment for patients.
How similar studies have performed: Other studies have explored biomarkers for sepsis diagnosis, but this specific approach focusing on immune responses in the emergency setting is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or higher * Presentation at the Emergency Department (ED) * Clinical suspicion of infection or earlier confirmed infection * Modified Early Warning Score (MEWS) of 2 or higher Exclusion Criteria: * No informed consent given
Where this trial is running
Almere Stad, Flevoland and 2 other locations
- Flevoziekenhuis — Almere Stad, Flevoland, Netherlands (Not_yet_recruiting)
- Amsterdam UMC, location VUMC — Amsterdam, North Holland, Netherlands (Recruiting)
- Amsterdam UMC, location AMC — Amsterdam, North Holland, Netherlands (Recruiting)
Study contacts
- Principal investigator: Willem Joost Wiersinga, MD, PhD — Amsterdam UMC, location AMC
- Study coordinator: Oren Turgman, MD, MsC
- Email: biosep@amsterdamumc.nl
- Phone: 0205669111
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.